ClinicalTrials.gg
CompletedNCT02881840Updated Jun 25, 2019Results posted

Mass-balance Study of [14C]-APD421 in Healthy Volunteers

A Phase 1 interventional study of 14C-APD421 in Post-operative Nausea and Vomiting, sponsored by Acacia Pharma Ltd. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Acacia Pharma Ltd · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

Open-label, non-randomised, single dose study in 6 healthy male subjects to assess the mass balance recovery, metabolite profile, metabolite identification and pharmacokinetics of 14C-labelled APD421

02

Conditions studied

  • Post-operative Nausea and Vomiting

Browse trials for

03

In context

Vomiting

794 studies on the registry are indexed under Vomiting; 98 are open to participants now.

This study's enrollment of 6 is below the median of 102 across 674 interventional studies indexed under Vomiting.

Browse Vomiting studies →

Lead sponsor

Acacia Pharma Ltd is the lead sponsor of 18 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males
  • Age 18 to 65 years of age at time of signing
  • (BMI) of 18 to 30 kg/m2 or, if outside the range, considered not by the investigator
  • Must be willing and able to communicate and participate in the whole study
  • Must provide written informed consent
  • Must agree to use an adequate method of (as defined in Section 8.4)
  • Must have regular bowel movements (ie average stool production of ≥1 and ≤3 stools per day)

Exclusion criteria

Exclusion Criteria:

  • Prior participation in another study with a radiation burden of > 0.1 mSv and ≤ 1 mSv in the period of 1 year prior to screening; a radiation burden of > 1 mSv and ≤ 2 mSv in the period of 2 years prior to screening; a radiation burden of > 2 mSv and ≤ 3 mSv in the period of 3 years prior to screening, etc (add 1 year per 1 mSv)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    14C-APD421

    Drug: 14C-APD421

Interventions

  • Drug14C-APD421
06

What researchers measure

Primary outcomes

  1. Mass Balance

    Mean recovery of radioactivity in excreta after a single intravenous (IV) dose of carbon-14-labelled APD421

    Time frame: 168 hours

07

Results

Posted Jun 7, 2019
Limitations and caveats
There were no limitation or caveats in this study.

Participant flow

Participant flow — Overall Study
Milestone14C-APD421
Started6
Completed6
Not completed0

Outcome measures

PrimaryMass Balance

Mean recovery of radioactivity in excreta after a single intravenous (IV) dose of carbon-14-labelled APD421

Time frame:
168 hours
Reported as:
Mean · percent excreted
Mass Balance
percent excreted14C-APD421
Mass Balance96.4 (92.0 to 98.5)

Adverse events

Collected over For the 7 day period after study drug administration. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
14C-APD4210/6 (0%)0/6 (0%)6/6 (100%)
Most frequent other events
Most frequent other events
Event14C-APD421
Infusion site painGeneral disorders6/6
FlatulenceGastrointestinal disorders2/6
Eye irritationEar and labyrinth disorders1/6
NauseaGastrointestinal disorders1/6
Catheter site inflammationGeneral disorders1/6
WoundInjury, poisoning and procedural complications1/6
DizzinessNervous system disorders1/6
HeadacheNervous system disorders1/6
SomnolenceNervous system disorders1/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)14C-APD421 Amisulpride
<=18 years0
Between 18 and 65 years6
>=65 years0
Age, Continuous
Age, Continuous(Years)14C-APD421 Amisulpride
Mean23 ± 3
Sex: Female, Male
Sex: Female, Male(Participants)14C-APD421 Amisulpride
Female0
Male6
Region of Enrollment
Region of Enrollment(Years)14C-APD421 Amisulpride
Netherlands6
08

Study locations

1 site
  • PRA Health Sciences
    Groningen, Netherlands
09

References and documents

Publications

  • Fox GM, Roffel AF, Hartstra J, Bussian LA, van Marle SP. Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers. Clin Pharmacol. 2019 Dec 2;11:161-169. doi: 10.2147/CPAA.S234256. eCollection 2019. PubMed 31819674 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2016, a primary completion of Aug 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2016
First posted
Aug 29, 2016
Start
Aug 2016
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results first posted
Jun 7, 2019
Last update
Jun 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02881840
Lead sponsor
Acacia Pharma Ltd
Responsible party
Sponsor
First posted
Aug 29, 2016
Start date
Aug 2016
Primary completion
Aug 2016
Completion
Aug 2016
Results posted
Jun 7, 2019
Last update
Jun 25, 2019

Study contacts

Gabriel Fox, MB BChir
study director · Acacia Pharma Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion